An Employer-Based Cost-Benefit Analysis of a Novel Pharmacotherapy Agent for Smoking Cessation
Authors:
- Robert NahoopiiRNRobert Nahoopii
- Qayyim SaidQSQayyim Said
- Riad DiraniRDRiad Dirani
- Diana BrixnerDBDiana Brixner
- 1 April 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Occupational and Environmental Medicine
- Vol. 49 (4) , 453-460
Abstract
An employer-based cost-benefit analysis for varenicline versus bupropion was conducted using clinical outcomes from a recently published trial. A decision tree model was developed based on the net benefit of treatment to produce a nonsmoker at 1 year. Sensitivity analyses were conducted based on quit rates with placebo and varenicline and the cost of varenicline. Estimated 12-month employer cost savings per non-smoking employee were $540.60 for varenicline, $269.80 for bupropion SR generic, $150.80 for bupropion SR brand, and $81.80 for placebo. Varenicline was more cost beneficial than placebo, which had quit rates of 16.9% or less. The quit rate with varenicline would have to be <or=16.9% to lose cost benefit over bupropion SR generic. The economic benefit of varenicline is improved over bupropion, despite the increased initial cost of varenicline.Keywords
This publication has 10 references indexed in Scilit:
- Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking CessationA Randomized Controlled TrialJAMA, 2006
- FDA Speeds Smoking Cessation Drug Review2006
- Reimbursement for smoking cessation treatment may double the abstinence rate: results of a randomized trialAddiction, 2005
- Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking CessationJournal of Medicinal Chemistry, 2005
- The Financial Implications of Coverage of Smoking Cessation Treatment by Managed Care OrganizationsINQUIRY: The Journal of Health Care Organization, Provision, and Financing, 2004
- Cost-effectiveness of the Clinical Practice Recommendations in the AHCPR Guideline for Smoking CessationJAMA, 1997
- The Health Care Costs of SmokingNew England Journal of Medicine, 1997
- Pharmacoeconomic Analysis of Smoking-cessation InterventionsAmerican Journal of Health-System Pharmacy, 1996
- How much can business expect to profit from smoking cessation?,Preventive Medicine, 1983
- Smoking and Carcinoma of the LungBMJ, 1950